IL-17 antagonist compositions for treating inflammatory arthritis

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted patent US12594333B2 to Novartis AG covering methods of treating inflammatory arthritis using IL-17 antagonists, specifically IL-17 binding molecules such as secukinumab antibodies. The patent contains 16 claims and covers therapeutic regimens for conditions including psoriatic arthritis.

View original document View source feed page

What changed

USPTO issued patent grant US12594333B2 to Novartis AG for compositions and methods of treating inflammatory arthritis using IL-17 antagonists including secukinumab. The patent covers IL-17 binding molecules and receptor binding molecules as therapeutic agents. The filing date was February 24, 2025, and the grant date is April 7, 2026.

For pharmaceutical companies and healthcare providers, this patent establishes exclusive rights that may affect licensing negotiations, generic drug development timelines, and therapeutic approach selections for inflammatory arthritis patients. Novartis gains 20-year patent protection for these therapeutic regimens in the United States.

What to do next

Monitor for updates

Source document (simplified)

← USPTO Patent Grants

Methods of treating inflammatory arthritis using IL-17 antagonists

Grant US12594333B2 Kind: B2 Apr 07, 2026

Assignee

NOVARTIS AG

Inventors

Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek

Abstract

The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).